Fred Alger Management, LLC Adc Therapeutics Sa Transaction History

Fred Alger Management, LLC

  • $19.7 Billion
  • Q4 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$1.92 - $5.45 $241,891 - $686,618
125,985 New
125,985 $245,000
Q4 2020

Feb 16, 2021
SELL
$25.26 - $38.02 $693,563 - $1.04 Million
-27,457 Closed
0 $0
Q3 2020

Nov 13, 2020
SELL
$32.87 - $51.05 $247,938 - $385,070
-7,543 Reduced 21.55%
27,457 $906,000
Q2 2020

Aug 14, 2020
BUY
$29.65 - $46.81 $1.04 Million - $1.64 Million
35,000 New
35,000 $1.64 Million

Others Institutions Holding ADCT

# of Institutions
85
Shares Held
55.3M
Call Options Held
24.1K
Put Options Held
44.7K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $125M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Fred Alger Management, LLC Portfolio

Follow Fred Alger Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fred Alger Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email